跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 40,859 条关于
“KCNT1-related catastrophic epilepsy”
全部
40,859
临床试验
29,738
药物
204
机构
104
资讯
10,813
28天前
Eight-month-old becomes first in world to receive precision medicine for KCNT1-related catastrophic epilepsy
3个月前
Servier Enrolls First Patient in Phase Ib/II Trial of ASO Therapy for KCNT1-Related Pediatric Epilepsy
去年
Actio Biosciences Receives FDA Clearance and Fast Track Designation for First-in-Class KCNT1 Epilepsy Treatment
前天
Jazz Pharmaceuticals Completes $820M Actio Biosciences Acquisition, Adding First-in-Class KCNT1 Epilepsy Candidate ABS-1230
上个月
Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million, Securing First-in-Class KCNT1 Epilepsy Therapy ABS-1230
4个月前
Actio Biosciences Initiates Phase 1b/2 Trial of ABS-1230 for Rare Pediatric Epilepsy
去年
Actio Biosciences Raises $66M Series B to Advance Rare Disease Programs Targeting Ion Channel Disorders
去年
Atalanta Therapeutics Secures $97 Million to Advance RNAi Therapies for Neurological Disorders
去年
Cassava Sciences Appoints Joseph Hulihan as Chief Medical Officer to Lead Simufilam Development for TSC-Related Epilepsy
2个月前
Personalized ASO Gene Therapy Dramatically Reduces Seizures and Restores Walking in Children with SCN2A-Related Epilepsy
第 1 页，共 1082 页
上一页
下一页
